



# VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY

## REPORT ON AUDIT FOR THE YEAR ENDED JUNE 30, 2014

Auditor of Public Accounts  
Martha S. Mavredes, CPA  
[www.apa.virginia.gov](http://www.apa.virginia.gov)  
(804) 225-3350



## AUDIT SUMMARY

We have audited the basic financial statements of the Virginia Biotechnology Research Partnership Authority as of and for the year ended June 30, 2014, and issued our report thereon, dated October 27, 2014. Our report, included in the Authority's Annual Report, is available on the Auditor of Public Accounts' website at [www.apa.virginia.gov](http://www.apa.virginia.gov).

Our audit of the Authority for the year ended June 30, 2014, found:

- the financial statements are presented fairly, in all material respects;
- no internal control findings requiring management's attention; and
- no instances of noncompliance or other matters required to be reported under Government Auditing Standards.

## –TABLE OF CONTENTS–

	<u>Pages</u>
AUDIT SUMMARY	
INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS	1 - 2
AUTHORITY OFFICIALS	3



Martha S. Mavredes, CPA  
Auditor of Public Accounts

# Commonwealth of Virginia

*Auditor of Public Accounts*

P.O. Box 1295  
Richmond, Virginia 23218

October 27, 2014

The Honorable Terence R. McAuliffe  
Governor of Virginia

The Honorable John C. Watkins  
Chairman, Joint Legislative Audit  
And Review Commission

Board Members  
Virginia Biotechnology Research Partnership Authority Board  
Virginia Biotechnology Research Park Corporation Board

## **INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS**

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States, the financial statements of the business-type activities and discretely presented component unit of the **Virginia Biotechnology Research Partnership Authority** (Authority) as of and for the year ended June 30, 2014, and the related notes to the financial statements, which collectively comprise the Authority's basic financial statements, and have issued our report thereon dated October 27, 2014.

### **Internal Control Over Financial Reporting**

In planning and performing our audit of the financial statements, we considered the Authority's internal control over financial reporting to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Authority's internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Authority's internal control over financial reporting.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over financial reporting was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over financial reporting that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Authority's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.

### **Purpose of this Report**

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Audit Standards in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

We discussed this report with management at an exit conference held on October 29, 2014.

AUDITOR OF PUBLIC ACCOUNTS

ZLB/alh

## **VIRGINIA BIOTECHNOLOGY RESEARCH PARTNERSHIP AUTHORITY**

As of June 30, 2014

Michael Rao, Chair

Mary Doswell, Vice Chair

Samuel B. Hunter, Secretary

Joy Edgett, Assistant Treasurer and Secretary to the Board

Carrie Roth, Interim Executive Director

Douglas E. Harvey

Gail Letts

Dwight C. Jones

Maurice Jones

Tonya Mallory

Zobair M. Younossi

## **VIRGINIA BIOTECHNOLOGY RESEARCH PARK CORPORATION**

As of June 30, 2014

Michael Rao, Chair

Charles H. Foster, Jr., Vice Chair

Samuel B. Hunter, Secretary

Joy Edgett, Assistant Treasurer and Secretary to the Board

Carrie Roth, Interim President and CEO

Donna Owens Cox

Ed A. Grier

Cecil R. Harris, Jr.

Douglas E. Harvey

Dwight C. Jones

Maurice Jones

Francis L. Macrina

Carlton E. Miller

Brandon J. Price

James J. L. Stegmaier

James A. Strickland

John Vithoulikas

William H. Weirich

William S. White

Patricia M. Woolsey